Onsdag 1 Juli | 06:19:35 Europe / Stockholm
Est. tid*
2027-02-24 08:30 Bokslutskommuniké 2026
2026-11-02 12:00 Kvartalsrapport 2026-Q3
2026-08-05 12:00 Kvartalsrapport 2026-Q2
2026-05-31 - Kvartalsrapport 2026-Q1
2026-05-27 - X-dag ordinarie utdelning MAGLE 0.00 SEK
2026-05-26 - Extra Bolagsstämma 2026
2026-05-26 - Årsstämma
2026-03-27 - Bokslutskommuniké 2025
2025-11-14 - Kvartalsrapport 2025-Q3
2025-08-01 - Kvartalsrapport 2025-Q2
2025-05-27 - X-dag ordinarie utdelning MAGLE 0.00 SEK
2025-05-26 - Årsstämma
2025-05-22 - Kvartalsrapport 2025-Q1
2025-03-27 - Bokslutskommuniké 2024
2024-12-30 - Extra Bolagsstämma 2025
2024-10-24 - Kvartalsrapport 2024-Q3
2024-10-04 - Extra Bolagsstämma 2024
2024-07-18 - Kvartalsrapport 2024-Q2
2024-04-26 - X-dag ordinarie utdelning MAGLE 0.00 SEK
2024-04-25 - Årsstämma
2024-04-18 - Kvartalsrapport 2024-Q1
2024-02-16 - Bokslutskommuniké 2023
2023-10-25 - Kvartalsrapport 2023-Q3
2023-07-18 - Kvartalsrapport 2023-Q2
2023-04-27 - X-dag ordinarie utdelning MAGLE 0.00 SEK
2023-04-26 - Årsstämma
2023-02-16 - Bokslutskommuniké 2022
2022-11-09 - Kvartalsrapport 2022-Q3
2022-08-17 - Kvartalsrapport 2022-Q2
2022-05-19 - X-dag ordinarie utdelning MAGLE 0.00 SEK
2022-05-17 - Årsstämma
2022-05-05 - Kvartalsrapport 2022-Q1
2022-02-25 - Bokslutskommuniké 2021
2021-12-14 - Extra Bolagsstämma 2021
2021-11-16 - Kvartalsrapport 2021-Q3
2021-08-17 - Kvartalsrapport 2021-Q2
2021-05-14 - Kvartalsrapport 2021-Q1
2021-05-03 - X-dag ordinarie utdelning MAGLE 0.00 SEK
2021-04-18 - Årsstämma
2021-02-25 - Bokslutskommuniké 2020
2020-11-27 - Extra Bolagsstämma 2020
2020-11-05 - Kvartalsrapport 2020-Q3
2020-07-14 - Kvartalsrapport 2020-Q2
LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Magle Chemoswed bygger på strategiska förvärv som syftar till att driva tillväxt och diversifiera risker. Koncernen omfattar tre verksamhetsområden. Magle Chemoswed, en kontraktsutvecklings- och tillverkningsorganisation (CDMO). Magle PharmaCept, ett försäljnings- och marknadsföringsföretag för utveckling och direktförsäljning av koncernens medicintekniska produkter, och Magle Biopolymers A/S, en specialiserad tillverkningsorganisation för Dextran-teknologi.

Analysera bolaget i Börsdata!

All ägardata du vill ha finns i Holdings!

Magle Group enters into agreement with Danske Bank regarding repayment schedule and agreement with the bondholders committee regarding the requirement for additional capital

2026-06-30 21:53:00

Magle Chemoswed Holding AB (publ) ("Magle" or the "Company") has today, on 30 June 2026, entered into (i) an agreement with Danske Bank A/S regarding repayment schedule and (ii) an agreement with the bondholders’ committee regarding the requirement for additional capital.

Agreed repayment schedule

As previously disclosed on 7 June 2026, the Company has a SEK 32.5 million credit facility with Danske Bank A/S (the "Danske Bank Facility") which was scheduled to mature on 30 June 2026. The Company today, on 30 June 2026, announces that it has reached an agreement with Danske Bank A/S regarding a structured repayment schedule for the outstanding amount under the Danske Bank Facility. The key terms of the agreed repayment schedule are as follows:

  • a repayment of SEK 15 million to be made by 31 August 2026;
  • the remaining outstanding amount to be repaid by 30 October 2026; and
  • interest for the extended period to accrue at the ordinary rate of STIBOR 90 +1.75% applicable under the Danske Bank Facility (i.e., not at any default rate).

The agreed repayment schedule provides the Company with additional time to manage its liquidity position and supports the Company's continued operations and long-term development.

Agreement with the bondholders’ committee regarding the requirement for additional capital

Pursuant to the written procedure in respect of its senior secured floating rate bonds with ISIN SE0025197403 submitted by the Company on 26 March 2026, and accepted by the bondholders on 23 April 2026, the bondholders agreed that the maintenance test contained in the terms and conditions for the bonds should not be tested on the reference dates falling 31 December 2025 until (and including) 31 December 2026, provided that, if the Issuer fails to raise no less than SEK 100 million, or such lower amount as agreed between the Company and the bondholders' committee, by 30 June 2026, the maintenance test shall be reinstated.

As part of the ongoing discussions between the Company and the bondholders' committee regarding a restructuring of the Company’s outstanding financing, the bondholders' committee has today, on 30 June 2026, agreed that the amount required to be raised by the Company for the maintenance test to not be reinstated shall be equal to zero.